Are We Poised to Change the Trajectory of Maintenance Oral Corticosteroid Use in Severe Asthma in the Age of Biologics?
Authors:
Abstract
No abstract availableFunding Information
- Sanofi
- Genentech
- Teva Pharmaceutical Industries
- GlaxoSmithKline
- Regeneron Pharmaceuticals
- Amgen
- AstraZeneca
- Novartis
This publication has 10 references indexed in Scilit:
- Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe AsthmaChest, 2022
- Mapping geographic variability of severe uncontrolled asthma in the United StatesAnnals of Allergy, Asthma & Immunology, 2022
- Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm studyThe Lancet Respiratory Medicine, 2022
- Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension studyThe Lancet Respiratory Medicine, 2022
- Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal PolyposisJournal of Asthma and Allergy, 2021
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working GroupJournal of Allergy and Clinical Immunology, 2020
- Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational studyJournal of Asthma and Allergy, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaNew England Journal of Medicine, 2018
- Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe AsthmaNew England Journal of Medicine, 2017
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaNew England Journal of Medicine, 2014